2. Search Result
Search Result
Results for "

DOX

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

9

Peptides

9

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100489
    TBHQ
    Maximum Cited Publications
    122 Publications Verification

    tert-Butylhydroquinone

    		 Environmental Pollutants Keap1-Nrf2 ERK Autophagy Apoptosis Ferroptosis Cancer
    TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .
    TBHQ
  • HY-B0006B
    (S)-Carvedilol

    (S)-BM 14190

    		 Adrenergic Receptor Cardiovascular Disease
    (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .
    (S)-Carvedilol
  • HY-N6635
    trans-Nerolidol

    		Fungal Infection Cancer
    trans-Nerolidol improves the anti-proliferative effect of Doxorubicin (DOX) (HY-15142A) against intestinal cancer and breast cancer cells in vitro. trans-Nerolidol increases accumulation of DOX inside cells in vitro. trans-Nerolidol activates apoptosis in vivo .
    trans-Nerolidol
  • HY-N2591
    Isocorydine

    		Endogenous Metabolite Cancer
    Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
    Isocorydine
  • HY-150644
    S07-2010
    1 Publications Verification

    		 Aldose Reductase Cancer
    S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
    S07-2010
  • HY-134599
    (2E)-TCO-PNB ester

    		Biochemical Assay Reagents Cancer
    (2E)-TCO-PNB ester is an active reaction substrate with the properties of trans-cyclooctene derivatives. The core chemical property of (2E)-TCO-PNB ester is its ability to undergo efficient inverse electron-demand Diels-Alder (IEDDA) cycloaddition with tetrazine groups. (2E)-TCO-PNB ester can be used in ligation reactions to verify the integrity of tetrazine groups, and also serves as a key synthetic raw material for the preparation of the prodrug TCO-DOX. (2E)-TCO-PNB ester is applied in research related to drug synthesis and bioorthogonal chemistry .
    (2E)-TCO-PNB ester
  • HY-122182
    OTS193320

    		Histone Methyltransferase Apoptosis Cancer
    OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .
    OTS193320
  • HY-B0006C
    (R)-Carvedilol

    (R)-BM 14190

    		 Adrenergic Receptor Calcium Channel Cardiovascular Disease Cancer
    (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca 2+ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .
    (R)-Carvedilol
  • HY-N6022
    Byakangelicin

    		Others Metabolic Disease
    Byakangelicin, one of the active compounds found in the roots of Angelica gigas, can serve as a modulator to improve brain accumulation of diverse active compounds (Umb, Cur, and Dox) and enhance therapeutic effects . Byakangelicin is likely to increase the expression of all PXR target genes (such as MDR1) and induce a wide range of agent-agent interactions. Byakangelicin can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones .
    Byakangelicin
  • HY-153797
    Dox-btn2

    Biotin Labeled DOXorubicin

    		 ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV HBV Apoptosis Autophagy Mitophagy Infection Cancer
    Dox-btn2 is a biotin labeled Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH2. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm .
    Dox-btn2
  • HY-160062
    S2.2 aptamer sodium

    		Mucin Cancer
    S2.2 aptamer sodium is a nucleic acid-based MUC1-binding aptamer with high affinity and low toxicity. Upon binding to its target, S2.2 aptamer sodium undergoes a conformational switch and restores fluorescence signal, serving as a targeted imaging agent for MUC1-positive cancer cells. S2.2 aptamer sodium enables targeted delivery to breast cancer cells with overexpressed MUC1. When formulated as the S2.2-PEG-MZF molecular probe, S2.2 aptamer sodium possesses the functions of T2 signal inhibition, magnetic field-induced hyperthermia and targeted magnetic resonance molecular imaging. In the S2.2-PEG-MZF/DOX nanoliposome, S2.2 aptamer sodium supports targeted thermochemotherapy, effectively inhibiting cancer cell proliferation and invasion as well as inducing apoptosis, and is widely used in studies related to breast cancer .
    S2.2 aptamer sodium
  • HY-160774
    Val-Cit-PABC-DOX

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC .
    Val-Cit-PABC-DOX
  • HY-100489R
    TBHQ (Standard)
    1 Publications Verification

    tert-Butylhydroquinone (Standard)

    		 Reference Standards Keap1-Nrf2 ERK Autophagy Apoptosis Ferroptosis Cancer
    TBHQ (Standard) is the analytical standard of TBHQ. This product is intended for research and analytical applications. TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .
    TBHQ (Standard)
  • HY-110122
    AZ 12216052
    1 Publications Verification

    		 mGluR Neurological Disease
    AZ 12216052 is a mGluR8 positive allosteric modulator, and helps mGluR8 modulate signaling inputing to retinal ganglion cells. AZ 12216052 exhibits antianxiety effect .
    AZ 12216052
  • HY-176869
    EMC-AANL-DOX

    		Drug Derivative Cancer
    EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX) (HY-15142A). EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26). EMC-AANL-DOX can be used for cancer research .
    EMC-AANL-DOX
  • HY-158329
    Alloc-DOX

    N-Alloc DOXorubicin

    		 Apoptosis Topoisomerase Antibiotic AMPK Bacterial Autophagy Mitophagy HIV HBV Cancer
    Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth .
    Alloc-DOX
  • HY-152188
    AKR1C3-IN-9

    		Aldose Reductase Cancer
    AKR1C3-IN-9 is a selective inhibitor of Aldo-keto Reductase 1C3 (AKR1C3) with an IC50 value of 8.92 nM. AKR1C3-IN-9 significantly reverses the Doxorubicin (HY-15142A) (DOX) resistance in a resistant breast cancer cell line .
    AKR1C3-IN-9
  • HY-P11455A
    Lipopeptide CPE4 TFA

    		Liposome Others
    Lipopeptide CPE4 TFA is a PEG-modified peptide E4 [(EIAALEK) 4]. Lipopeptide CPE4 TFA is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPE4 TFA triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPE4 TFA can be used for drug delivery research .
    Lipopeptide CPE4 TFA
  • HY-D2437
    DOX-PEG-Cy3

    		Fluorescent Dye Antibiotic Cardiovascular Disease Cancer
    DOX-PEG-Cy3 (Doxorubicin-PEG-Cy3) is a Cy3 (HY-D0822) labeled DOX-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. DOX is a broad-spectrum anthracycline antibiotic with cytotoxic properties .
    DOX-PEG-Cy3
  • HY-P10760
    PhAc-ALGP-Dox

    		Peptide-Drug Conjugates (PDCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-155391
    hCA/Wnt/β-catenin-IN-1

    		Carbonic Anhydrase P-glycoprotein Wnt β-catenin Cancer
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .
    hCA/Wnt/β-catenin-IN-1
  • HY-125907
    Dox-Ph-PEG1-Cl

    PROTAC Linker 34

    		 PROTAC Linkers Cancer
    Dox-Ph-PEG1-Cl (PROTAC Linker 34) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs .
    Dox-Ph-PEG1-Cl
  • HY-N11638
    Ganoderic acid R

    		Apoptosis Cancer
    Ganoderic acid R is a potent anticancer agent. Ganoderic acid R inhibits the growth by inducing apoptosis on tumor cell line. Ganoderic acid R possesses significant cytotoxicity on a multidrug resistance (MDR) tumor cell line (KB-A-1/Dox) and a sensitive tumor cell line (KB-A-1) .
    Ganoderic acid R
  • HY-179247
    BCR-ABL1-IN-2

    		Bcr-Abl Cancer
    BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research .
    BCR-ABL1-IN-2
  • HY-125807
    IS20

    		G Protein-coupled Receptor Kinase (GRK) Apoptosis Reactive Oxygen Species (ROS) Akt p38 MAPK Cardiovascular Disease Cancer
    IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin (HY-15142A) mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin-induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research .
    IS20
  • HY-P11456A
    Lipopeptide CPK4 TFA

    		Liposome Others
    Lipopeptide CPK4 TFA is a Cholesterol (HY-N0322)-modified peptide K4 [(KIAALKE) 3]. Lipopeptide CPK4 TFA is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPK4 TFA triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPK4 TFA can be used for drug delivery research .
    Lipopeptide CPK4 TFA
  • HY-P10770
    P-ESBP-DOX

    		Peptide-Drug Conjugates (PDCs) E-Selectin Cardiovascular Disease Cancer
    P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .
    P-ESBP-DOX
  • HY-163078
    C2-Gal-Dox

    		Drug Derivative Cancer
    C2-Gal-Dox is a galactose conjugate with high cytotoxicity. C2-Gal-Dox inhibits the growth of a variety of cancer cells .
    C2-Gal-Dox
  • HY-172191
    Czapek dox agar

    		Biochemical Assay Reagents Others
    Czapek dox agar can be used to identify and preserve strains of Penicillium and Aspergillus .
    Czapek dox agar
  • HY-144825
    Chol-CTPP

    		Apoptosis Reactive Oxygen Species (ROS) Cancer
    Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .
    Chol-CTPP
  • HY-N10642
    Pedaliin 6''-acetate

    		Others Others
    Pedaliin 6''-acetate (compound 10) is a natural product that can be isolated from Dracocephalum tanguticum. Pedaliin 6''-acetate shows antioxidative activity and cytoprotective effect on doxorubicin (DOX)-induced toxicity in H9c2 cardiomyocytes with an EC50 value of 19.1 μM .
    Pedaliin 6''-acetate
  • HY-144769
    SDOX

    		Topoisomerase Cancer
    SDOX is the Doxorubicin (DOX) proagent. The loaded DOX proagents (SDOX) which can release the parent agents DOX triggered by excessive GSH in tumor cells, minimize the unexpected side effects on normal tissues without compromising the potency .
    SDOX
  • HY-157484
    P-gp inhibitor 19

    		P-glycoprotein Cancer
    P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .
    P-gp inhibitor 19
  • HY-155035
    S07-1066

    		17β-HSD Cancer
    S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells .
    S07-1066
  • HY-157483
    P-gp inhibitor 18

    		P-glycoprotein Cancer
    P-gp inhibitor 18 (compound 6G) is a potent inhibitor of P-gp. P-gp inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .
    P-gp inhibitor 18
  • HY-N6635R
    trans-Nerolidol (Standard)

    		Reference Standards Fungal Infection Cancer
    trans-Nerolidol (Standard) is the analytical standard of trans-Nerolidol. This product is intended for research and analytical applications. trans-Nerolidol improves the anti-proliferative effect of Doxorubicin (DOX) (HY-15142A) against intestinal cancer and breast cancer cells in vitro. trans-Nerolidol increases accumulation of DOX inside cells in vitro. trans-Nerolidol activates apoptosis in vivo .
    trans-Nerolidol (Standard)
  • HY-N2591A
    Isocorydine hydrochloride

    		Endogenous Metabolite Cancer
    Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
    Isocorydine hydrochloride
  • HY-N2591R
    Isocorydine (Standard)

    		Reference Standards Endogenous Metabolite Cancer
    Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
    Isocorydine (Standard)
  • HY-P2004
    FFAGLDD

    		MMP Cancer
    FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
    FFAGLDD
  • HY-N13157
    11α-O-Benzoyl-12β-O-acetyltenacigenin B

    		P-glycoprotein Cancer
    11α-O-Benzoyl-12β-O-acetyltenacigenin B is a P-glycoprotein (Pgp) inhibitor derived from Marsdenia tenacissima and belongs to the Tenacigenin B (HY-N1168) derivatives. 11α-O-Benzoyl-12β-O-acetyltenacigenin B can inhibit multidrug resistance (MDR) caused by P-glycoprotein (Pgp) overexpression in HepG2/Dox cells and holds potential for research in the field of cancer .
    11α-O-Benzoyl-12β-O-acetyltenacigenin B
  • HY-P2004A
    FFAGLDD TFA

    		MMP Cancer
    FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
    FFAGLDD TFA
  • HY-B0006BR
    (S)-Carvedilol (Standard)

    (S)-BM 14190 (Standard)

    		 Reference Standards Adrenergic Receptor Cardiovascular Disease
    (S)-Carvedilol (Standard) is the analytical standard of (S)-Carvedilol. This product is intended for research and analytical applications.
    (S)-Carvedilol (Standard)
  • HY-B0006BS
    (S)-Carvedilol-d4

    (S)-BM 14190-d4

    		 Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease
    (S)-Carvedilol-d4 is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .
    (S)-Carvedilol-d4
  • HY-163363
    β-AR antagonist 2

    		Adrenergic Receptor Cancer
    β-AR antagonist 2 (compound 43) is an antagonist of β-AR (IC50: 0.17 μM). β-AR-IN-1 inhibits the growth of mouse A549 xenograft tumors and shows cardioprotective efficacy against DOX-induced HF in C57 mice .
    β-AR antagonist 2
  • HY-177869
    CHNQD-00824

    		Drug Derivative Apoptosis Caspase PARP Cancer
    CHNQD-00824 is a Terphenyllin (HY-119821) derivative with potent anticancer effect. CHNQD-00824 inhibits the proliferation and migration of cancer cells via DNA damage. CHNQD-00824 triggers apoptosis and inhibits Doxycin Hydrochloride (DOX)-induced liver-specific enlargement in zebrafish embryos. CHNQD-00824 can be used for cancer research, such as liver and breast cancer .
    CHNQD-00824
  • HY-150648
    S07-2008

    		Aldose Reductase Cancer
    S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 of 0.16 μM. S07-2008 shows anticancer activities .
    S07-2008
  • HY-173132
    AKR1Cs-IN-1

    		Aldose Reductase Cancer
    AKR1Cs-IN-1 (Compound 29) is a potent and broad-spectrum inhibitor targeting members of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). By simultaneously occupying the SP2 and SP3 pockets, it effectively inhibits multiple isoforms and disrupts metabolic pathways associated with drug resistance. In enzymatic activity assays, AKR1Cs-IN-1 exhibited significant inhibitory potency, with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM against AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. In the doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, AKR1Cs-IN-1 showed remarkable resensitization effects and significantly enhanced the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on overcoming drug resistance in breast cancer .
    AKR1Cs-IN-1
  • HY-181546
    Ibt-DOX

    		Btk PERK Syk HMG Family Cancer
    Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research .
    Ibt-DOX
  • HY-P11455
    Lipopeptide CPE4

    		Liposome Others
    Lipopeptide CPE4 is a PEG-modified peptide E4 [(EIAALEK) 4]. Lipopeptide CPE4 is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPE4 triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPE4 can be used for drug delivery research .
    Lipopeptide CPE4
  • HY-122224
    SW43

    		Sigma Receptor Cancer
    SW43 is a Sigma-2 selective ligand and agonist. SW43 is an ideal molecule for the development of cancer-targeted drug compounds. SW43 conjugated with DOX-L-NETA ( 89Y) exhibits antitumor activity in a VX2 cancer liver tumor allograft rabbit model. SW 43 conjugated with SW IV-52s to form SW III-123 activates the NF-κB pathway, has potent cytotoxicity against ovarian cancer cell lines, and induces apoptosis .
    SW43

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: